Introduction {#s1}
============

Cannabinoid CB~2~ receptor (CB~2~) agonists show efficacy in animal models of chronic inflammatory and neuropathic pain, suggesting that they may be effective inhibitors of persistent pain in humans ([@bib5]; [@bib34]; [@bib54]). However, many preclinical studies assess reflexive-defensive reactions to evoked nociceptive stimuli and fail to take into account spontaneous pain, one of the most prevalent symptoms of chronic pain conditions in humans ([@bib3]; [@bib40]; [@bib49]) that triggers coping responses such as analgesic consumption. As a consequence, conclusions drawn from animal models relying on evoked nociception may not translate into efficient pharmacotherapy in humans ([@bib24]; [@bib39]; [@bib45]), which underlines the need to apply more sophisticated animal models with clear translational value. Operant paradigms in which animals voluntarily self-administer analgesic compounds can provide high translatability and also identify in the same experimental approach potential addictive properties of the drugs ([@bib39]; [@bib40]; [@bib43]). In this line, a previous work using a CB~2~ agonist, AM1241, showed drug-taking behavior in nerve-injured rats and not in sham-operated animals, suggesting spontaneous pain relief and lack of abuse potential of CB~2~agonists ([@bib20]), although the possible cell populations and mechanisms involved remain unknown. In addition, a recent multicenter study demonstrated off-target effects of this compound on anandamide reuptake, calcium channels and serotonin, histamine and kappa opioid receptors ([@bib55]).

CB~2~, the main cannabinoid receptors in peripheral immune cells ([@bib17]; [@bib52]), are found in monocytes, macrophages and lymphocytes, and their expression increases in conditions of active inflammation ([@bib53]; [@bib54]). The presence of CB~2 ~in the nervous system was thought to be restricted to microglia and limited to pathological conditions or intense neuronal activity ([@bib36]). However, recent studies using electrophysiological approaches and tissue-specific genetic deletion revealed functional CB~2~ also in neurons, where they modulate dopamine-related behaviors ([@bib60]) and basic neurotransmission ([@bib46]; [@bib57]). Remarkably, the specific contribution of immune and neuronal CB~2~ to the development of chronic pathological pain has not yet been established.

This work investigates the participation of neuronal and non-neuronal cell populations expressing CB~2~ in the development and control of chronic neuropathic pain. We used a pharmacogenetic strategy combining tissue-specific CB~2~ deletion and drug self-administration to investigate spontaneous neuropathic pain. Constitutive and conditional knockouts lacking CB~2~ in neurons or monocytes were nerve-injured, subjected to operant self-administration of the specific CB~2~ agonist JWH133 ([@bib55]) and were evaluated for nociceptive and anxiety-like behavior. We also explored infiltration of CB~2~-positive immune cells in the injured nerve of mice receiving bone marrow transplants from CB~2~-GFP BAC mice. Finally, immunological blockade of lymphocyte extravasation was used to investigate the effect of this cell type on spontaneous neuropathic pain and its involvement on the pain-relieving effects of the cannabinoid CB~2~ agonist.

Results {#s2}
=======

Self-administration of a CB~2~ receptor agonist to alleviate spontaneous pain and anxiety-associated behavior {#s2-1}
-------------------------------------------------------------------------------------------------------------

CB~2~ agonists have shown efficacy reducing evoked sensitivity and responses of negative affect in mouse models of chronic pain ([@bib34]). Although antinociception is a desirable characteristic for drugs targeting chronic neuropathic pain, it is unclear whether the pain-relieving effects of the CB~2~ agonist would be sufficient to elicit drug-taking behavior in mice and the cell populations involved. To answer these questions, mice underwent a PSNL or a sham surgery and were placed in operant chambers where they had to nose poke on an active sensor to obtain i.v. self-administration of the CB~2~ agonist JWH133 or vehicle ([Figure 1A](#fig1){ref-type="fig"}). Sham mice or nerve-injured animals receiving vehicle or the low dose of JWH133 (0.15 mg/kg/inf) did not show significant differences in active nose-poking during the last 3 days of the drug self-administration period ([Figure 1B](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). Conversely, nerve-injured mice exposed to the high dose of JWH133 (0.3 mg/kg/inf) showed higher active responses than sham-operated mice receiving the same treatment ([Figure 1B](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). As expected, the operant behavior of sham-operated mice exposed to JWH133 was not different from that of sham mice exposed to vehicle, suggesting absence of reinforcing effects of the CB~2~ agonist in mice without pain ([Figure 1B](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). The number of nose pokes on the inactive sensor was similar among the groups, indicating absence of locomotor effects of the surgery or the pharmacological treatments. Thus, operant JWH133 self-administration was selectively associated to the neuropathic condition.

![C57BL/6J mice self-administer a CB~2~ receptor agonist with antinociceptive and anxiolytic-like properties.\
(**A**) Timeline of the drug self-administration paradigm. Mice were trained in Skinner boxes (5 days, 5d) where nose-poking an active sensor elicited delivery of food pellets. Partial sciatic nerve ligation (PSNL) or sham surgery were conducted (day 0) followed by jugular catheterization to allow intravenous (i.v.) drug infusion. From days 7 to 18, mice returned to the operant chambers and food was substituted by i.v. infusions of JWH133 (0.15 or 0.3 mg/kg/inf.). Mechanical and thermal sensitivity were assessed before (−1) and 3, 6 and 18 days after PSNL using Plantar and von Frey tests. Anxiety-like behavior was measured at the end (day 19) with the elevated plus maze. (**B**) Nerve-injured mice poked the active sensor to consume the high dose of JWH133 (0.3 mg/kg/inf.). (**C**) PSNL-induced ipsilateral thermal and mechanical sensitization (days 3 and 6). JWH133 inhibited thermal hypersensitivity but the effect on mechanical nociception was not significant ([**D**]{.smallcaps}) Nerve-injured mice receiving vehicle showed decreased percentage of entries to the open arms of the elevated plus maze, whereas PSNL mice receiving JWH133 0.3 mg/kg/inf. did not show this alteration. N = 5--10 mice per group. Shaded areas represent drug self-administration. Mean and error bars representing SEM are shown. Stars represent comparisons vs. sham; diamonds vs. vehicle. \*p\<0.05; \*\*p\<0.01; \*\*\*p\<0.001.\
Figure 1---source data 1.JWH133 self-administration, antinociception and anxiolytic-like effects in C57BL6/J mice.](elife-55582-fig1){#fig1}

Nociceptive responses to thermal and mechanical stimuli were assessed before and after the self-administration period (days −1, 3, 6 and 18). Before the treatment with the CB~2~ agonist, all nerve-injured mice developed heat and mechanical hypersensitivity in the ipsilateral paw ([Figure 1C](#fig1){ref-type="fig"}). After self-administration (shaded area, [Figure 1C](#fig1){ref-type="fig"}) mice exposed to JWH133 showed a significant reduction in heat hypersensitivity ([Figure 1C](#fig1){ref-type="fig"}, day 18, ipsilateral paw), although the alleviation of mechanical hypersensitivity did not reach statistical significance in this experiment. No significant drug effects were observed in the contralateral paws.

We also studied affective-like behavior in mice exposed to this chronic pain condition. Anxiety-like behavior was enhanced in nerve-injured mice treated with vehicle, as these mice visited less frequently the open arms of the elevated plus maze ([Figure 1D](#fig1){ref-type="fig"}). This emotional response was absent in nerve-injured mice repeatedly exposed to the high dose of JWH133 ([Figure 1D](#fig1){ref-type="fig"}). Therefore, the high dose of JWH133 elicited a drug-taking behavior selectively associated to spontaneous pain relief, and had efficacy limiting the pronociceptive effects of the nerve injury and its emotional-like consequences.

CB~2~ receptor mediates JWH133 effects on spontaneous pain alleviation {#s2-2}
----------------------------------------------------------------------

JWH133 has been recently recommended as a selective CB~2~ agonist to study the role of CB~2~ in biological and disease processes due to its high selectivity for this receptor ([@bib55]). To investigate the specificity of the CB~2~ agonist in our model, the high dose of JWH133 (0.3 mg/kg/inf) was offered to nerve-injured mice constitutively lacking the CB~2~ (CB~2~ KO) and to C57BL/6J wild-type mice. CB~2~ KO mice showed a significant disruption of JWH133-taking behavior on the last sessions of the drug self-administration period ([Figure 2A](#fig2){ref-type="fig"}, [Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}). Overall discrimination between the active and inactive sensors was also significantly blunted in CB~2~ KO mice (Source Data File) and inactive nose pokes were similar in both groups of mice, indicating absence of genotype effect on locomotion ([Figure 2A](#fig2){ref-type="fig"}, [Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}). The disruption of drug-taking behavior shown in CB~2~ KO mice was accompanied by an inhibition of JWH133 effects on nociceptive and affective behavior ([Figure 2B](#fig2){ref-type="fig"}, [Figure 2C](#fig2){ref-type="fig"}).

![Nerve-injured mice constitutively lacking CB~2~ receptor show disruption of JWH133 intake and blunted effects of the drug.\
CB~2~ constitutive knockout mice (CB~2~ KO) and C57BL/6J mice were food-trained in Skinner boxes (Food training, 5 days), subjected to a partial sciatic nerve ligation (PSNL, day 0), catheterized and exposed to high doses of the CB~2~ agonist JWH133 (0.3 mg/kg/inf., days 7 to 18). Nociceptive sensitivity to heat (Plantar) and mechanical (von Frey) stimulation were measured before and after the nerve injury (−1,3,6,18), and anxiety-like behavior was evaluated at the end (day 19). (**A**) CB~2~ KO mice showed decreased active operant responding for the CB~2~ agonist. (**B**) The effects of JWH133 on thermal nociception were reduced in constitutive knockout mice. CB~2~ KO mice showed contralateral mechanical and thermal sensitization and complete abolition of JWH133 effects on mechanical hypersensitivity. (**C**) Anxiety-like behavior after the treatment worsened in CB~2~ KO mice. N = 16--19 mice per group. Mean and error bars representing SEM are shown. Shaded areas represent drug self-administration. Stars represent comparisons vs. C57BL/6J mice; crosses represent day effect. \*p\<0.05; \*\*p\<0.01; \*\*\*p\<0.001.\
Figure 2---source data 1.JWH133 self-administration, antinociception and anxiolytic-like effects in nerve-injured CB~2~ constitutive knockout mice.](elife-55582-fig2){#fig2}

CB~2~ KO and C57BL/6J mice developed similar thermal and mechanical hypersensitivity in the injured paw ([Figure 2B](#fig2){ref-type="fig"}, day 6, Ipsilateral paw), although CB~2~ KO mice also developed hypersensitivity in the contralateral paw, as previously described ([@bib47]). While C57BL/6J mice showed significant recovery of thermal and mechanical thresholds after JWH133 self-administration ([Figure 2B](#fig2){ref-type="fig"}, day 18), CB~2~ KO mice showed no effects of the treatment on mechanical sensitivity ([Figure 2B](#fig2){ref-type="fig"}, day 18, Mechanical) and a partial recovery of the thresholds to heat stimulation ([Figure 2B](#fig2){ref-type="fig"}, day 18, Heat). Contralateral mechanical sensitization was still present in CB~2~ KO mice exposed to the CB~2~ agonist ([Figure 2B](#fig2){ref-type="fig"}, Contralateral paw). Likewise, nerve-injured C57BL/6J mice showed less anxiety-like behavior after JWH133 self-administration than CB~2~ KO mice ([Figure 2C](#fig2){ref-type="fig"}), suggesting that these anxiolytic-like effects of JWH133 are mediated by CB~2~. Hence, CB~2~ KO mice showed reduced drug-taking behavior accompanied by blunted inhibition of JWH133 effects on mechanical nociception and anxiety-like behavior, confirming mediation of these effects by CB~2~.

JWH133 has shown effects interacting with the Transient Receptor Potential Ankyrin1 (TRPA1) ([@bib55]), a receptor needed for thermal pain perception ([@bib59]), that could also participate in other nociceptive responses. In order to assess a possible effect of the CB2 agonist on TRPA1 receptors in vivo, we conducted an additional experiment in which we compared the antinociceptive efficacy of JWH133 in sham and nerve-injured TRPA1 knockout mice (TRPA1 KO) and wild-type mice. After 7 days of the nerve injury, vehicle or i.p. doses of JWH133 (5 and 10 mg/kg) were administered to nerve-injured and sham-operated mice, and mechanical and heat nociception were assessed 30 and 75 min later, respectively. We observed similar effects of JWH133 inhibiting mechanical hypersensitivity in TRPA1 KO and WT mice ([Figure 2---figure supplement 2A](#fig2s2){ref-type="fig"}). Interestingly, TRPA1 KO mice showed a prominent inhibition of neuropathic thermal hypersensitivity ([Figure 2---figure supplement 2B](#fig2s2){ref-type="fig"}). In spite of this lack of sensitivity, a significant general effect was observed in nerve-injured mice with the high dose of JWH133 (10 mg/kg), regardless of the genotype of the mice. Thus, the results on mechanical sensitivity suggest that these effects are not due to an interaction of the drug with the TRPA1 receptor. The lack of thermal hypersensitivity observed in the TRPA1 KO mice may occlude possible JWH133 effects on neuropathic thermal hyperalgesia through TRPA1; however, a significant effect of JWH133 was observed in both strains after the nerve injury, suggesting that at least the CB2 receptor is involved in the inhibitory effect on thermal hyperalgesia.

Participation of neuronal and monocyte CB~2~ receptor in neuropathic pain symptomatology {#s2-3}
----------------------------------------------------------------------------------------

CB~2~ receptors were initially described in peripheral immune cells ([@bib41]), although they have been found in multiple tissues including the nervous system. In order to distinguish the participation of CB~2~ from different cell types on spontaneous neuropathic pain, we conducted the self-administration paradigm in nerve-injured mice lacking CB~2~ in neurons (Syn-Cre+ mice) or in monocyte-derived cells (LysM-Cre+) and in their wild-type littermates (Cre Neg). Syn-Cre+ mice showed increased active operant responding for JWH133 ([Figure 3A](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}), suggesting increased spontaneous pain and possible decrease of drug effects. On the other hand, LysM-Cre+ mice did not show significant alteration of drug-taking behavior ([Figure 3A](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}). Inactive responding was also similar between Cre Neg and knockout mice. Thus, data from the drug self-administration experiments showed persistence of drug effects in the different genotypes and increased self-administration in mice lacking neuronal CB~2~, suggestive of increased spontaneous pain.

![Nerve-injured mice defective in neuronal CB~2~ receptor show increased self-administration of the CB~2~ agonist JWH133 and a decrease in the antinociceptive effects of the drug.\
Mice lacking CB~2~ in neurons (Syn-Cre+), in monocytes (LysM-Cre+) or their wild-type littermates (Cre Neg) were food-trained in Skinner boxes (Food training, 5 days), subjected to partial sciatic nerve ligation (PSNL, day 0), catheterized and exposed to JWH133 (0.3 mg/kg/inf., days 7 to 18). Nociceptive sensitivity to heat (Plantar) and mechanical (von Frey) stimulation were measured before and after nerve injury (−1,3,6,18), anxiety-like behavior was evaluated at the end (day 19). (**A**) Syn-Cre+ mice showed increased active operant responding for JWH133 in the last sessions of the self-administration period (**B**) All mouse strains showed decreased heat nociception after JWH133 treatment, and Syn-Cre+ mice showed reduced effects of JWH133 on mechanical nociception. (**C**) Every mouse strain showed similar anxiety-like behavior after JWH133 self-administration. No significant differences were found between LysM-Cre+ and Cre Neg mice. N = 18--36 mice per group. Mean and error bars representing SEM are shown. Shaded areas represent drug self-administration. Stars represent comparisons vs. Cre Neg mice; crosses represent day effect. \*p\<0.05; \*\*p\<0.01; \*\*\*p\<0.001.\
Figure 3---source data 1.JWH133 self-administration, antinociception and anxiolytic-like effects in nerve-injured neuronal or microglial CB~2~ knockout mice.](elife-55582-fig3){#fig3}

We also measured antinociceptive and anxiolytic-like effects of JWH133 self-administration ([Figure 3B](#fig3){ref-type="fig"}, [Figure 3C](#fig3){ref-type="fig"}). The three mouse lines showed similar evoked responses to nociceptive stimulation after nerve injury ([Figure 3B](#fig3){ref-type="fig"}). A slight but significant impairment on the effect of JWH133 on mechanical sensitivity was found in Syn-Cre+ mice ([Figure 3C](#fig3){ref-type="fig"}) in spite of the increased JWH133 consumption, compatible with reduced efficacy of JWH133 in this mouse strain. The assessment of anxiety-like behavior did not reveal apparent differences among the three genotypes ([Figure 3C](#fig3){ref-type="fig"}). Thus, the increased JWH133 consumption observed in Syn-Cre+ mice was not reflected in increased anxiolysis and JWH133 antinociceptive effects were blunted, suggesting partial involvement of neuronal CB~2~ in the development of spontaneous and evoked neuropathic pain. To investigate a possible involvement of peripheral neuronal CB~2~ on the antinociceptive effects of JWH133, an additional experiment was performed in floxed CB~2~ mice expressing Cre recombinase in Nav1.8+ primary afferents (Nav1.8-Cre+, lacking CB~2~ only in primary afferent nociceptive fibers, [Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}), and in floxed littermates lacking Cre (Cre Neg). After 7 days of the nerve injury, vehicle or i.p. doses of JWH133 (5 and 10 mg/kg) were administered to nerve-injured and sham-operated mice, and mechanical and heat nociception were assessed 30 and 75 min later, respectively. No significant differences were observed between both genotypes in mechanical or thermal sensitivity ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}) revealing that CB~2~ primarily expressed in nociceptors were not involved in the antinociceptive effects of JWH133.

Infiltration of non-neuronal CB~2~ receptor-GFP+ cells in the injured nerve {#s2-4}
---------------------------------------------------------------------------

The persistence of JWH133 effects after genetic deletion of CB~2~ from neurons and monocyte-derived cells led us to hypothesize that CB~2~ of other cell types may still exert neuromodulatory effects. To investigate possible infiltration of non-neuronal GFP+ cells in the injured nerve, we transplanted bone marrow cells from C57BL/6J or CB~2~-GFP BAC mice to lethally irradiated CB57BL/6J-recipient mice ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). Mice transplanted with bone marrow from CB~2~-GFP mice (CB~2~ -GFP BMT) or from C57BL/6J mice (C57BL/6J BMT) were exposed to a partial sciatic nerve ligation or a sham surgery and dorsal root ganglia were collected 14 days later. A significant infiltration of non-neuronal GFP+ cells was revealed in nerve injured CB~2~-GFP BMT mice (\~30 cells/mm^2^, [Figure 4A](#fig4){ref-type="fig"}, [Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}), indicating that CB~2~ -expressing cells invaded the injured nerve. Immunostaining to identify these cell types revealed co-localization with macrophage and lymphocyte markers. Nearly 60% of infiltrating macrophages and around 40% of the lymphocytes were found to be GFP+ ([Figure 4B](#fig4){ref-type="fig"}, [Figure 4C](#fig4){ref-type="fig"}, [Figure 4---figure supplement 3](#fig4s3){ref-type="fig"}). Surprisingly, a significant percentage of neurons was also found to express GFP in CB~2~-GFP BMT mice ([Figure 4D](#fig4){ref-type="fig"}). The percentage of GFP+ neurons was higher in nerve-injured mice (\~4% of total neurons) than in sham-operated animals (\~2%, [Figure 4D](#fig4){ref-type="fig"}, [Figure 4---figure supplement 4](#fig4s4){ref-type="fig"}). Since GFP could only come from bone-marrow transplanted cells, this finding suggests a transfer of CB~2~ from bone-marrow derived cells to neurons. Hence, nerve injury facilitated the invasion of affected ganglia by CB~2~-positive immune cells and promoted a neuronal GFP expression compatible with transfer of CB~2~ from immune cells to neurons.

![CB~2~ receptor-GFP immune cells infiltrate the dorsal root ganglia of the injured nerve and GFP from bone-marrow-derived cells is also found inside peripheral neurons.\
The figure shows images of L3-L5 dorsal root ganglia from sham (SHAM) or nerve-injured mice (PSNL) transplanted with bone marrow cells from CB~2~ GFP BAC mice (CB~2~-GFP) or C57BL6/J mice (C57BL6/J). (**A, D**) Dorsal root ganglia sections stained with the nuclear marker DAPI (Blue), anti-GFP (Green), and neuronal markers anti-β-III tubulin and anti-peripherin (Red). (**A**) CB~2~-GFP mice showed significant infiltration of GFP+ bone-marrow-derived cells after the nerve injury, whereas sham or nerve-injured C57BL6/J mice did not show significant GFP immunorreactivity. Split channels in [Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}. (**B**) Co-localization of CB~2~-GFP and the macrophage marker anti-F4/80. Co-staining with anti-GFP and anti-F4/80 revealed GFP+ (\~60%) and GFP negative macrophages infiltrating the injured nerve. Split channels in [Figure 4---figure supplement 3A](#fig4s3){ref-type="fig"}. (**C**) Co-staining with anti-GFP and anti-CD45 revealed GFP+ (\~40%) and GFP-negative lymphocytes infiltrating the injured nerve. Split channels in [Figure 4---figure supplement 3B](#fig4s3){ref-type="fig"}. (**D**) CB~2~-GFP mice showed a percentage of GFP+ neurons that was enhanced with the nerve injury. Scale bar, 140 μm. Split channels in [Figure 4---figure supplement 4](#fig4s4){ref-type="fig"}. Scale bar for B), C), D), 45 μm. Yellow arrows point to GFP negative cells and white arrows to GFP+ cells. A certain degree of image processing has been applied equally across the entire merged images for optimal visualization. N = 2--3 mice per group. Means and error bars representing SEM are shown. Stars represent comparisons vs. sham; diamonds vs. C57BL6/J. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001. Flow cytometry of blood from CB~2~-GFP and C57BL6/J mice in [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}. Additional images of Sham and nerve-injured CB~2~-GFP mice in [Figure 4---figure supplements 5](#fig4s5){ref-type="fig"} and [6](#fig4s6){ref-type="fig"}. Specificity tests for Tyramide Signal Amplification in [Figure 4---figure supplement 7](#fig4s7){ref-type="fig"}. Controls for antibody specificity in [Figure 4---figure supplement 8](#fig4s8){ref-type="fig"}.\
Figure 4---source data 1.CB~2~ GFP cells in dorsal root ganglia of C57BL6/J nerve-injured mice after bone-marrow transplants from CB~2~ GFP BAC mice.](elife-55582-fig4){#fig4}

Lymphocyte involvement on JWH133 efficacy {#s2-5}
-----------------------------------------

The discovery of CB~2~-expressing lymphocytes invading the dorsal root ganglia of nerve-injured mice prompted us to investigate the role of this cell type in spontaneous neuropathic pain. To answer this question, C57BL/6J mice were repeatedly treated with a control IgG or with an antibody targeting intercellular adhesion molecule 1 (ICAM1), a protein required for lymphocyte extravasation ([@bib30]). Mice under treatment with anti-ICAM1 or with the control IgG were exposed to JWH133 self-administration. Instead of reducing the intake of the CB~2~ agonist, anti-ICAM1 significantly increased active nose poking to obtain i.v. JWH133 without altering the inactive nose poking ([Figure 5A](#fig5){ref-type="fig"}, [Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}), suggesting increased spontaneous pain. This result is in agreement with previous works showing protection against chronic inflammatory and neuropathic pain mediated by lymphoid cells ([@bib30]; [@bib4]). Interestingly, thermal and mechanical nociception before self-administration were similar in anti-ICAM1 and control IgG-treated mice ([Figure 5B](#fig5){ref-type="fig"}). After self-administration, the alleviation of thermal sensitivity was similar in control IgG and anti-ICAM1-treated mice ([Figure 5B](#fig5){ref-type="fig"}), but mice treated with anti-ICAM1 also showed an abolition of the antinociceptive effect of JWH133 on mechanical sensitivity ([Figure 5B](#fig5){ref-type="fig"}). This was evident in spite of the increased drug-taking behavior shown by mice treated with anti-ICAM1 ([Figure 5A](#fig5){ref-type="fig"}), which reveals decreased antinociceptive efficacy of JWH133 in these mice. On the contrary, anxiety-like behavior was similar in Control IgG and anti-ICAM1 mice ([Figure 5C](#fig5){ref-type="fig"}). To confirm an effect of the antibody treatment on lymphocyte infiltration, RT-PCR for white blood cell markers was performed in the dorsal root ganglia of mice subjected to the behavioral paradigm. As expected, a significant decrease in T cell markers CD2 and CD4 was observed in mice treated with anti ICAM-1 ([Figure 5D,T](#fig5){ref-type="fig"} cell panel). Interestingly, anti ICAM-1 also showed a pronounced increase in B cell marker CD19 ([Figure 5D](#fig5){ref-type="fig"}) and no alteration of the macrophage marker C1q ([Figure 5D](#fig5){ref-type="fig"}). Hence, our results reveal that lymphoid cells are involved in spontaneous neuropathic pain and are also necessary for the antinociceptive effect of JWH133 on mechanical sensitivity.

![Lymphocytes modulate the effects of JWH133 on spontaneous pain and mechanical nociception.\
C57BL/6J mice were food-trained in Skinner boxes (Food training, 5 days), subjected to partial sciatic nerve ligation (PSNL, day 0), catheterized and exposed to high doses of the CB~2~ agonist JWH133 (0.3 mg/kg/inf., days 7 to 18). Treatments with Anti-ICAM1 (an antibody that inhibits lymphocyte extravasation) or control IgG were given intraperitoneally once a day from day 0 until the end of self-administration. Nociceptive sensitivity to heat (Plantar) and mechanical (von Frey) stimulation was measured before and after nerve injury (−1,3,6,18), and anxiety-like behavior was evaluated at the end (day 19). Dorsal root ganglia were collected for mRNA analysis ([**A**]{.smallcaps}) Mice treated with anti-ICAM1 showed increased active responding for JWH133. (**B**) Thermal nociception after JWH133 self-administration was similar in mice treated with anti-ICAM1 or control IgG. Conversely, JWH133 effects on mechanical nociception were abolished by anti-ICAM1. (**C**) Anxiety-like behavior was similar in anti-ICAM1 and control IgG mice. (**D**) Levels of mRNA from T cell markers CD2 and CD4 were decreased in the dorsal root ganglia of anti-ICAM1 mice. Conversely, levels of B cell marker CD19 increased. Macrophage marker C1q was unaffected. N = 6--7 mice per group. Shaded areas represent drug self-administration. Mean and error bars representing SEM are shown. Stars represent comparisons vs. control IgG group; crosses indicate day effect. \*p\<0.05; \*\*p\<0.01; \*\*\*p\<0.001.\
Figure 5---source data 1.JWH133 self-administration, antinociception and anxiolytic-like effects in nerve-injured C57BL6/J mice treated with anti-ICAM1.](elife-55582-fig5){#fig5}

Discussion {#s3}
==========

This work shows a protective function of CB~2~ from neurons and lymphocytes on spontaneous neuropathic pain and the involvement of these cell populations in CB~2~-induced antinociception, as revealed by increased self-administration of the CB~2~ agonist JWH133 in mice defective in lymphocyte and neuronal CB~2~. Previous works already demonstrated antinociceptive and emotional-like effects of CB~2~ agonists in rodent models of acute and chronic pain ([@bib20]; [@bib25]; [@bib26]; [@bib29]; [@bib34]). Our results provide evidence that the effect of the CB~2~ agonist is sufficient to promote drug-taking behavior in nerve-injured mice for alleviation of spontaneous pain, but it is void of reinforcing effects in animals without pain, suggesting the absence of abuse liability. This absence of reinforcement adds value to the modulation of pain through CB~2~ agonists, since current available agents for neuropathic pain treatment have reduced efficacy and often show addictive properties in humans and rodents ([@bib2]; [@bib7]; [@bib11]; [@bib18]; [@bib22]; [@bib43]).

A previous work using the CB~2~ agonist AM1241 showed drug-taking behavior and antinociception in nerve-injured rats ([@bib20]), although a recent multicenter study demonstrated off-target effects of this drug ([@bib55]). The disruption of JWH133 effects observed in constitutive knockout mice confirms that the relief of spontaneous pain and the effects reducing mechanical nociception and anxiety-like behavior are mediated by CB~2~ stimulation. However, the CB~2~ agonist partially preserved its effects promoting drug self-administration and relieving thermal hypersensitivity in CB2KO mice, suggesting that JWH133 may also act through other receptors. Our results with the nerve-injured TRPA1 knockout mice revealed that JWH133 preserves its efficacy inducing antinociception in the absence of this receptor. Therefore, TRPA1 does not seem to play a relevant role in the antinociceptive response induced by JWH133 in our model of neuropathic pain mice. Interestingly, TRPA1 deletion prevented the development of thermal hyperalgesia after the nerve injury in our study and formalin (0.5%) evoked nocifensive behaviors are also lost in the TRPA1 knockout ([@bib38]). Another possibility is a minor involvement of CB~1~ receptor in JWH133 self-administration after the nerve injury, since this compound is a selective CB~2~ agonist that exhibited 40-fold higher affinity for mouse CB~2~ than for CB~1~ receptor ([@bib55]). Our experiments were not designed to rule out this possible minor participation. However, the inactive responding in the operant self-administration sessions was similar after JWH133 or vehicle in nerve-injured mice, indicating an absence of primary CB~1~-related side effects such as motor alteration that are classical effects observed in mice after the administration of CB~1~ agonists ([@bib51]). Previous works using higher equivalent doses of a CB~2~ agonist with similar potency ([@bib55]) showed also absence of motor impairment in nerve-injured rats ([@bib20]). Since JWH133 selectivity for human CB~2~ vs. human CB~1~ is higher (153-fold selectivity), we do not foresee any concern with CB1-related behavioral effects using similar molecules in humans.

Nerve-injured mice defective in neuronal CB~2~ showed higher JWH133 intake than wild-type littermates, indicating persistence of drug effects and increased spontaneous pain when neurons do not express CB~2~. Thus, increased self-administration suggests an enhanced affective-motivational component of pain and not reduced drug efficacy on this aspect, since nerve-injured C57BL6/J mice exposed to the low JWH133 dose did not show compensatory increased self--administration ([Figure 1](#fig1){ref-type="fig"}). Importantly, mechanical and thermal neuropathic hypersensitivity before drug self-administration were similar in neuronal knockouts and their wild-type littermates, which suggests different mechanisms of spontaneous pain and evoked nociception. In addition, mechanical nociception measured after JWH133 was more severe in neuronal CB~2~ knockouts than in wild-type littermates, which indicates decreased JWH133 efficacy on mechanical antinociception. Several studies described the presence of CB~2~ mRNA and functional CB~2~ receptor in neuronal populations from different areas of the rain ([@bib57]; [@bib60]). However, other works using targeted expression of fluorescent proteins under the control of the mouse gene *Cnr2* failed to describe CB~2~ expression in neurons ([@bib33]; [@bib52]). Our results agree with a role of neuronal CB~2~ during painful neuroinflammatory conditions, a setting that was not studied before in mice defective in neuronal CB~2~. Although we cannot provide a precise localization of the neurons involved in the increased spontaneous and evoked pain of neuronal knockout mice, the similar JWH133 response of CB~2~ Nav1.8 Cre+ mice lacking CB~2~ in primary afferent neurons (Nav1.8-Cre+) and wild-type mice could indicate involvement of a different set of neurons or increased relevance of CB~2~ from immune sources. Thermal hypersensitivity and anxiety-like behavior measured after self-administration was similar in neuronal knockouts and wild-type mice, which indicates involvement of non-neuronal cell populations. However, it should also be considered that the neuronal knockout mice had higher JWH133 consumption. Thus, a possible lack of efficacy could also be present for thermal antinociception and inhibition of anxiety-like behavior. Although a neuronal involvement was found, CB~2~ neuronal knockouts did not recapitulate the phenotype of mice constitutively lacking CB~2~, suggesting additional cell types involved in the effects of CB~2~agonists.

We investigated the effects of JWH133 promoting its own consumption and inducing antinociception and anxiolysis in CB~2~ LysM-Cre+ mice, mainly lacking CB~2~ in monocytes, the precursors of microglial cells. We did not observe a microglial participation in these pain-related phenotypes, which may be due to an incomplete deletion of CB~2~ in microglia through LysM-driven Cre expression ([@bib6]). Previous studies in mice constitutively lacking CB~2~ described an exacerbated spinal cord microgliosis after nerve injury ([@bib42]; [@bib47]), which suggested a relevant role of CB~2~ controlling glial reactivity. Since spinal microgliosis participates in the increased pain sensitivity after a neuropathic insult and macrophages and microglia express CB~2~, blunted effects of JWH133 were expected in microglial CB~2~ knockouts. However, monocyte-derived cells did not seem to be involved in the analgesic effects mediated by the exogenous activation of CB~2~ in these experimental conditions.

The immunohistochemical analysis of dorsal root ganglia from mice transplanted with bone marrow cells of CB~2~GFP BAC mice ([@bib52]) revealed a pronounced infiltration of immune cells expressing CB~2~ in the dorsal root ganglia after nerve injury. Macrophages and lymphocytes expressing CB~2~ were found at a time point in which nerve-injured mice present mechanical and thermal hypersensitivity and self-administer compounds with demonstrated analgesic efficacy ([@bib10]; [@bib11]). Interestingly, GFP expression was also found in neurons, suggesting a transfer of CB~2~ from peripheral immune cells to neurons. An explanation for this finding may come from processes of cellular fusion or transfer of cargo between peripheral blood cells and neurons ([@bib1]; [@bib50]). Bone-marrow-derived cells fuse with different cell types in a process of cellular repair that increases after tissue damage. These events may be particularly important for the survival of neurons with complex structures that would otherwise be impossible to replace ([@bib19]). Alternatively, extracellular vesicles drive intercellular transport between immune cells and neurons ([@bib9]). Earlier studies showed incidence of fusion events between bone-marrow-derived cells and peripheral neurons in a model of diabetic neuropathy ([@bib58]), and similar processes were observed in central neurons after peripheral inflammation ([@bib19]; [@bib50]). Functional contribution of these mechanisms to neuronal CB~2~ expression has not yet been explored, although cargo transfer between immune cells and neurons could modify neuronal functionality and it could offer novel therapeutic approaches to modulate neuronal responses ([@bib9]). Hence, CB~2~ coming from white blood cells and present in neurons could be significant modulators of spontaneous neuropathic pain and may be contributors to the analgesic effect of CB~2~ agonists.

Our results suggest participation of lymphoid cells on spontaneous neuropathic pain, but not on basal neuropathic hypersensitivity, highlighting possible differences on the pathophysiology of these nociceptive manifestations. In addition, lymphoid cells were essential for the effects of JWH133 alleviating mechanical sensitivity after a nerve injury. These hypotheses were evaluated by using anti-ICAM1 antibodies that impair lymphocyte extravasation. Previous studies revealed that anti-ICAM1 treatment inhibited opioid-induced antinociception in a model of neuropathic pain ([@bib12]; [@bib30]). According to the authors, stimulation of opioid receptors from the immune cells infiltrating the injured nerve evoked the release of opioid peptides that attenuated mechanical hypersensitivity. Lymphocyte CB~2~ could also be involved in the release of leukocyte-derived pain-modulating molecules. Experiments assessing the function of ICAM1 ([@bib12]; [@bib15]; [@bib30]) showed the participation of this protein on lymphocyte extravasation. In agreement, we observed a decrease of T cell markers in the dorsal root ganglia of mice receiving anti-ICAM1. Anti-ICAM1 treatment also increased the mRNA levels of the B cell marker CD19 in the dorsal root ganglia. Since ICAM1-interacting T cells show activity limiting B cell populations ([@bib15]; [@bib62]), it is likely that the absence of T cells in the nervous tissue increased infiltration of B lymphocytes. B cells are involved in the severity of neuroinflammatory processes and have been linked to pain hypersensitivity ([@bib23]; [@bib27]; [@bib31]; [@bib61]). Interestingly, CB~2~ receptors restrict glucose and energy supply of B cells ([@bib13]), which may alter their cytokine production as previously described for macrophages and T cells. However, the participation of CB~2~ from B cells on neuropathic pain has not yet been established. Our results indicate an increase in JWH133 consumption that could be driven by an increased infiltration of B cells. Overall, the results with the ICAM-1 experiment suggest a relevant participation of lymphoid CB~2~ on painful neuroinflammatory responses. Our data also underscore the interest of investigating the role of lymphoid cells in brain regions involved in pain, anxiety or negative reinforcement during chronic neuroinflammatory processes.

While we identify CB~2~-expressing neurons and lymphocytes as cellular entities involved in spontaneous and evoked neuropathic pain, the efficacy of the CB~2~ agonist eliciting its own self-administration to alleviate pain was only disrupted in constitutive CB~2~ knockout mice. These results indicate that the cell types involved in the negative reinforcement induced by JWH133 were suboptimally targeted in our experimental conditions, probably because different cell types expressing CB~2~ are involved in this phenotype. Vascular cells may represent alternative participants of this behavior since JWH133 showed local vasodilatory effects ([@bib37]) and endothelial functional CB~2~ receptor was found in cerebral microvasculature ([@bib48]; [@bib44]).

In summary, the contribution of neurons and lymphocytes to the effects of CB~2~ agonists on spontaneous and evoked pain suggests a coordinated response of both cell types after the nerve injury. CB~2~-expressing lymphocytes could participate in pain sensitization through release of pain-related molecules and the observed responses are also compatible with transfer of CB~2~ between immune cells and neurons. Hence, bone-marrow-derived cells may provide a source of functional CB~2~ that was not considered before and could clarify the controversial presence of these receptors in neurons. Nociceptive and affective manifestations of chronic neuropathic pain are therefore orchestrated through neuronal and immune sites expressing CB~2~, highlighting the functional relevance of this cannabinoid receptor in different cell populations.

Our results on operant JWH133 self-administration depict CB~2~ agonists as candidate analgesics for neuropathic conditions, void of reinforcing effects in the absence of pain. These pain-relieving effects involve the participation of CB~2~ from neurons and lymphocytes preventing the neuroinflammatory processes leading to neuropathic pain. Therefore, CB~2~ agonists would be of interest for preventing neuropathic pain development and the potential trials to evaluate this effect should consider starting CB~2~ agonist treatment before or shortly after the induction of neuropathic insults, as in our study, in contrast to the treatment strategies used in previous clinical trials. The identification of a cannabinoid agonist simultaneously targeting the behavioral traits and the multiple cell types involved in the pathophysiology of chronic neuropathic pain acquires special relevance in a moment in which the absence of efficient analgesics void of abuse liability has become a major burden for public health.

Materials and methods {#s4}
=====================

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                                      Designation                                                     Source or reference                                              Identifiers                                                              Additional information
  (species) or resource                                                                                                                                                                                                                                        
  -------------------------------------------------- --------------------------------------------------------------- ---------------------------------------------------------------- ------------------------------------------------------------------------ --------------------------------------------------------------------------------
  Strain, strain background (*Mus musculus*, male)   C57BL/6J                                                        Charles Rivers, France                                           RRID:[IMSR_JAX:000664](https://scicrunch.org/resolver/IMSR_JAX:000664)   

  Genetic reagent (*M. musculus*)                    CB~2~ KO                                                        Institute of Molecular Psychiatry, University of Bonn, Germany   RRID:[MGI:2663848](https://scicrunch.org/resolver/MGI:2663848)           [@bib8] PMID:[10822068](https://www.ncbi.nlm.nih.gov/pubmed/10822068) (male)

  Genetic reagent (*M. musculus*)                    SynCre+-Cnr2^fl/fl^:: Cnr2^fl/fl^                               Institute of Molecular Psychiatry, University of Bonn, Germany                                                                            (C57BL/6J background, male)

  Genetic reagent (*M. musculus*)                    LysMCre+-Cnr2^fl/fl^:: Cnr2^fl/fl^                              Institute of Molecular Psychiatry, University of Bonn, Germany                                                                            (C57BL/6J background, male)

  Genetic reagent (*M. musculus*)                    Nav1.8Cre+-Cnr2^fl/fl^:: Cnr2^fl/fl^                            Institute of Molecular Psychiatry, University of Bonn, Germany                                                                            (C57BL/6J background, male)

  Genetic reagent (*M. musculus*)                    TRPA1 KO                                                        Universidad Miguel Hernández, Spain                              RRID:[MGI:3625358](https://scicrunch.org/resolver/MGI:3625358)           [@bib28]. PMID:[16630838](https://www.ncbi.nlm.nih.gov/pubmed/16630838) (male)

  Strain, strain background (*M. musculus,* male)    C57BL/6JRccHsd                                                  Universidad Miguel Hernández, Spain                                                                                                       Envigo

  Antibody                                           Anti-mouse ICAM-1 (Hamster, monoclonal, clone 3e2)              BD Biosciences, USA                                              550287                                                                   (150 μg/day i.p.)

  Antibody                                           IgG from rabbit serum (Unconjugated)                            Sigma-Aldrich, Germany                                           I5006                                                                    (150 μg/day i.p.)

  Antibody                                           Allophycocyanin-conjugated anti-mouse CD11b (Monoclonal)        eBioscience, USA                                                 cn.17--0112                                                              Flow cytometry (1:300)

  Antibody                                           Phycoerythrin -conjugated anti-mouse B220 (Monoclonal)          eBioscience, USA                                                 cn.12--0452                                                              Flow cytometry (1:100)

  Antibody                                           Phycoerythrin/cyanine-conjugated anti-mouse CD3 (Monoclonal)    BioLegend, USA                                                   cn.100320                                                                Flow cytometry (1:100)

  Antibody                                           Rabbit anti-peripherin (Polyclonal)                             Thermo Fisher, USA                                               PA3-16723                                                                IHC (1:200)

  Antibody                                           Rabbit anti-GFP antibody (Polyclonal)                           Thermo Fisher, USA                                               A11122                                                                   IHC (1:2000)

  Antibody                                           Rabbit anti-β-III tubulin (Polyclonal)                          Abcam, UK                                                        Ab18207                                                                  IHC (1:1000)

  Antibody                                           Rat anti-CD45R/B220 APC antibody (Monoclonal, Clone RA3- 6B2)   Biolegend, USA                                                   103229                                                                   IHC (1:500)

  Antibody                                           Rat anti-F4/80 antibody (Monoclonal, Clone A3-1)                Biorad, USA                                                      MCA497GA                                                                 IHC (1:500)

  Antibody                                           Anti-rabbit poly-HRP-conjugated (Polyclonal)                    Thermo Fisher, USA                                               Tyramide Superboost Kit, B40922                                          IHC (1X)

  Antibody                                           Goat anti-rabbit Alexa Fluor A555 (Polyclonal)                  Abcam, UK                                                        Ab150078                                                                 IHC (1:1000)

  Antibody                                           Goat anti-rat Alexa Fluor A555 (Polyclonal)                     Abcam, UK                                                        Ab150158                                                                 IHC (1:1000)

  Chemical compound, drug                            JWH133                                                          Tocris, UK                                                       TO-1343                                                                  CB~2~ receptor agonist

  Chemical compound, drug                            Sodium thiopental                                               Braun medical, Spain                                             635573                                                                   

  Chemical compound, drug                            Isoflurane                                                      Virbac, Spain                                                    575837--4                                                                

  Chemical compound, drug                            Paraformaldehyde                                                Merck Millipore, Germany                                         104005                                                                   

  Chemical compound, drug                            DAPI Fluoromount-G mounting media                               SouthernBiotech, USA                                             0100--20                                                                 

  Commercial assay or kit                            RNeasy Micro kit                                                Qiagen, Germany                                                  74004                                                                    

  Commercial assay or kit                            Omniscript reverse transcriptase                                Qiagen, Germany                                                  205111                                                                   

  Commercial assay or kit                            Tyramide Superboost Kit                                         Thermo Fisher, USA                                               B40922                                                                   

  Software, algorithm                                FACSDiva version 6.2                                            BD biosciences, USA                                              RRID:[SCR_001456](https://scicrunch.org/resolver/SCR_001456)             

  Software, algorithm                                Fiji                                                            Wayne Rasband, USA                                               RRID:[SCR_002285](https://scicrunch.org/resolver/SCR_002285)             

  Software, algorithm                                IBM SPSS 19                                                     IBM Corporation, USA                                             RRID:[SCR_002865](https://scicrunch.org/resolver/SCR_002865)             

  Software, algorithm                                STATISTICA 6.0                                                  StatSoft, USA                                                    RRID:[SCR_014213](https://scicrunch.org/resolver/SCR_014213)             
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Animals {#s4-1}
-------

C57BL/6J male mice were purchased from Charles River Laboratories (L'Arbresle, France), and CB~2~ knockout male mice defective in the *Cnr2* gene were bred in the Institute of Molecular Psychiatry (University of Bonn, Bonn, Germany). CB~2~ constitutive knockouts were bred from heterozygous parents and their wild-type littermates were used as controls. Neuron and microglia/macrophage-specific conditional CB~2~ knockout mice were generated as previously described ([@bib57]). Briefly, mice expressing Cre recombinase under the *Synapsin I* promoter (Syn-Cre+), mice expressing Cre recombinase inserted into the first coding ATG of the *Lyz2* gene (LysM-Cre+) and mice expressing Cre under the promoter of the gene *Scn10a* that codes for Nav1.8 voltage-gated sodium channels (Nav1.8-Cre+) were crossed with *Cnr2* floxed animals (Cnr2^fl/fl^ mice) to obtain Cre+::Cnr2^fl/fl^ mice. These F1 mice (Syn-Cre+-Cnr2^fl/-^, LysM-Cre+-Cnr2^fl/-^ and Nav1.8-Cre+-Cnr2^fl/-^) were backcrossed to Cnr2^fl/fl^ mice to generate mice Cnr2^fl/fl^ and heterozygous for Cre (Cre+-Cnr2^fl/fl^). Syn-Cre+-Cnr2^fl/fl^ (Syn-Cre+), LysM-Cre+-Cnr2^fl/fl^ (LysM-Cre+) and Nav1.8-Cre+-Cnr2^fl/fl^ (Nav1.8-Cre+) mice were selected and further backcrossed to Cnr2^fl/fl^ mice to produce experimental cohorts Syn-Cre+-Cnr2^fl/fl^::Cnr2^fl/fl^, LysM-Cre+-Cnr2^fl/fl^::Cnr2^fl/fl^ and Nav1.8-Cre+-Cnr2^fl/fl^::Cnr2^fl/fl^ containing 50% conditional knockout animals (also referred to as neuronal knockouts or Syn-Cre+, microglial knockouds or LysM-Cre+ and Nav1.8 knockouts or Nav1.8-Cre+) and 50% littermate control animals (referred to as Cre Negative mice throughout the study). Mice defective in the *Trpa1* gene (TRPA1 knockouts, [@bib28]) and their respective control mice (C57BL/6JRccHsd) were bred in the animal facility at Universidad Miguel Hernández (UMH, Elche, Alicante, Spain). For bone-marrow transplantation studies, 2 CB~2~-GFP BAC mice ([@bib52]) or C57BL/6J mice were used as donors and C57BL/6J mice were used as recipient mice. All mice had a C57BL/6J genetic background. The behavioral experimental sequence involving operant self-administration and assessment of nociceptive and anxiety-like behavior was repeated three times in the experiments assessing the effects of JWH133 doses ([Figure 1](#fig1){ref-type="fig"}) and 4 and 5 times in the experiments evaluating constitutive and conditional knockout mice, respectively ([Figures 2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"}). The experiments involving bone-marrow transplantation and lymphocyte depletion were performed once. Sample size was based on previous studies in our laboratory using comparable behavioral approaches ([@bib10]; [@bib11]; [@bib29]).

The behavioral experiments were conducted in the animal facilities at Universitat Pompeu Fabra (UPF)-Barcelona Biomedical Research Park (PRBB; Barcelona, Spain) and UMH (Elche, Alicante, Spain). Mice were housed in temperature (21 ± 1°C) and humidity-controlled (55 ± 10%) rooms. For the self-administration experiments, animals were handled during the dark phase of a 12 hr light/dark reverse cycle (light off at 8:00 a.m., light on at 8:00 p.m.). Before starting the experimental procedure, mice were single housed and handled/habituated for 7 days. Food and water were available ad libitum except during the training period for food-maintained operant behavior, when mice were exposed to restricted diet for 8 days. Animal handling and experiments were in accordance with protocols approved by the respective Animal Care and Use Committees of the PRBB, Departament de Territori i Habitatge of Generalitat de Catalunya, UMH and the Institute of Molecular Psychiatry and were performed in accordance with the European Communities Council Directive (2010/63/EU). Whenever possible, animals were randomly assigned to their experimental condition, and experiments were performed under blinded conditions for surgery and pharmacological treatment ([Figure 1](#fig1){ref-type="fig"}), genotype ([Figures 2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"}), bone-marrow transplant and surgery ([Figure 4](#fig4){ref-type="fig"}), and antibody treatments ([Figure 5](#fig5){ref-type="fig"}).

Drugs {#s4-2}
-----

JWH133 (Tocris, Bristol, UK) was dissolved in vehicle solution containing 5% dimethyl sulfoxide (Scharlab, Sentmenat, Spain) and 5% cremophor EL (Sigma-Aldrich, Steinheim, Germany) in sterilized water and filtered with a 0.22 µm filter (Millex GP, Millipore, Cork, Ireland). JWH133 was self-administered intravenously (i.v.) at 0.15 or 0.3 mg/kg/infusion in volume of 23.5 μl per injection. In the additional experiments assessing nociceptive behavior in Nav1.8-Cre+ and TRPA1 knockout mice, JWH133 was diluted in a vehicle composed of 5% ethanol (Alcoholes Montplet, Barcelona, Spain), 5% Cremophor EL, and 90% saline (0.9% NaCl; Laboratorios Ern, Barcelona, Spain) to be administered intraperitoneally (i.p.) in a volume of 10 ml/kg. Thiopental (Braun Medical, Barcelona, Spain) was dissolved in saline and administered through the implanted i.v. catheter at 10 mg/kg in a volume of 50 μl.

Antibody treatment {#s4-3}
------------------

Anti-ICAM-1 antibody (clone 3E2; 150 μg; BD Biosciences, Franklin Lakes, NJ) and control rabbit IgG (150 μg; Sigma-Aldrich) were dissolved in saline up to a volume of 300 µl as previously reported ([@bib30]), and administered i.p. once a day from the day of the surgery to the last self-administration day.

Operant self-administration {#s4-4}
---------------------------

Mice were first trained for operant food self-administration to facilitate subsequent drug self-administration, as previously described ([@bib11]). Briefly, mice were food-restricted for 3 days to reach 90% of their initial weight. Then, mice were trained in skinner boxes (model ENV-307A-CT, Med Associates Inc, Georgia, VT) for 5 days (1 hr session per day) to acquire an operant behavior to obtain food pellets ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}, [Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"}, [Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}, [Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}). A fixed ratio 1 schedule of reinforcement (FR1) was used, that is 1 nose-poke on the active hole resulted in the delivery of 1 reinforcer together with a light-stimulus for 2 s (associated cue). Nose poking on the inactive hole had no consequence. Each session started with a priming delivery of 1 reinforcer and a timeout period of 10 s right after, where no cues and no reward were provided following active nose-pokes. Food sessions lasted 1 hr or until mice nose-poked 100 times on the active hole, whichever happened first. After the food training, mice underwent a partial sciatic nerve ligation (PSNL) or a sham surgery, and 4 days later an i.v. catheter was implanted in the right jugular vein to allow drug delivery. Mice started the drug self-administration sessions 7 days after the PSNL/sham surgery. In these sessions, the food reinforcer was substituted by drug/vehicle infusions. Self-administration sessions were conducted during 12 consecutive days, and mice received JWH133 (0.15 or 0.3 mg/kg) or vehicle under FR1 ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}, [Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"}, [Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}, [Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}). Sessions lasted 1 hr or until 60 active nose-pokes. Active and inactive nose-pokes were recorded after each session and discrimination indices were calculated as the difference between the nose pokes on the active and the inactive holes, divided by the total nose pokes. Data from the last three drug self-administration sessions was used for statistical analysis to exclude interference with food-driven operant behavior.

Partial Sciatic Nerve Ligation {#s4-5}
------------------------------

Mice underwent a partial ligation of the sciatic nerve at mid-thigh level to induce neuropathic pain, as previously described ([@bib35]) with minor modifications. Briefly, mice were anaesthetized with isoflurane (induction, 5% V/V; surgery, 2% V/V) in oxygen and the sciatic nerve was exposed at the level of the mid-thigh of the right hind leg. At \~1 cm proximally to the nerve trifurcation, a tight ligature was created around 33--50% of the cranial side of the sciatic nerve using a 9--0 non-absorbable virgin silk suture (Alcon Cusí SA, Barcelona, Spain) and leaving the rest of the nerve untouched. The muscle was then stitched with 6--0 silk (Alcon Cusí), and the incision was closed with wound clips. Sham-operated mice underwent the same surgical procedure except that the sciatic nerve was not ligated.

Catheterization {#s4-6}
---------------

Mice were implanted with indwelling i.v. silastic catheter, as previously reported ([@bib56]). Briefly, a 5.5 cm length of silastic tubing (0.3 mm inner diameter, 0.64 mm outer diameter; Silastic, Dow Corning Europe, Seneffe, Belgium) was fitted to a 22-gauge steel cannula (Semat Technical Ltd., Herts, UK) that was bent at a right angle and then embedded in a cement disk (Dentalon Plus, Heraeus Kulzer, Wehrheim, Germany) with an underlying nylon mesh. The catheter tubing was inserted 1.3 cm into the right jugular vein and anchored with suture. The remaining tubing ran subcutaneously to the cannula, which exited at the midscapular region. All incisions were sutured and coated with antibiotic ointment (Bactroban, GlaxoSmithKline, Madrid, Spain).

Nociception {#s4-7}
-----------

Sensitivity to heat and mechanical stimuli were used as nociceptive measures of neuropathic pain. Ipsilateral and contralateral hind paw withdrawal thresholds were evaluated the day before, 3 and 6 days after the nerve injury, as well as after the last self-medication session on day 18. Heat sensitivity was assessed by recording the hind paw withdrawal latency in response to radiant heat applied with the plantar test apparatus (Ugo Basile, Varese, Italy) as previously reported ([@bib21]). Punctate mechanical sensitivity was quantified by measuring the withdrawal response to von Frey filament stimulation through the up--down paradigm, as previously reported ([@bib14]). Filaments equivalent to 0.04, 0.07, 0.16, 0.4, 0.6, 1 and 2 g were used, applying first the 0.4 g filament and increasing or decreasing the strength according to the response. The filaments were bent and held for 4--5 s against the plantar surface of the hind paws. Clear paw withdrawal, shaking or licking was considered a nociceptive-like response. Four additional filaments were applied since the first change of response (from negative to positive or from positive to negative), once each time. The sequence of the last six responses was used to calculate the withdrawal threshold following the method described by [@bib16].

Anxiety-like behavior {#s4-8}
---------------------

Anxiety-like behavior was evaluated with an elevated plus maze made of Plexiglas and consisting of four arms (29 cm long x 5 cm wide), two open and two closed, set in cross from a neutral central square (5 × 5 cm) elevated 40 cm above the floor. Light intensity in the open and closed arms was 45 and 5 lux, respectively. Mice were placed in the neutral central square facing 1 of the open arms and tested for 5 min. The percentage of entries and time spent in the open and closed arms was determined.

RNA extraction and reverse transcription {#s4-9}
----------------------------------------

Ipsilateral L3-L4 dorsal root ganglia from mice of the ICAM-1 experiment were collected on day 20 after the PSNL. Samples were rapidly frozen in dry ice and stored at −80°C. Isolation of total RNA was performed using the RNeasy Micro kit (Qiagen, Stokach, Germany) according to the manufacturer's instructions. Total RNA concentration was measured using a NanoDrop ND-1000 Spectrophotometer (NanoDrop Technologies Inc, Montchanin, DE). RNA quality was determined by chip-based capillary electrophoresis using an Agilent Bioanalyzer 2100 (Agilent, Palo Alto, CA). Reverse transcription was performed using Omniscript reverse transcriptase (Qiagen) at 37°C for 60 min.

Quantitative real-time PCR analysis {#s4-10}
-----------------------------------

The qRT-PCR reactions were performed using Assay-On-Demand TaqMan probes: Hprt1 Mm01545399_m1, CD2 Mm00488928 m1, CD4 Mm00442754_m1, CD19 Mm00515420_m1, C1q Mm00432162_m1 (Applied Biosystems, Carlsbad, CA) and were run on the CFX96 Touch Real-Time PCR machine (BioRad, Hercules, CA). Each template was generated from individual animals, and amplification efficiency for each assay was determined by running a standard dilution curve. The expression of the Hprt1 transcript was quantified at a stable level between the experimental groups to control for variations in cDNA amounts. The cycle threshold values were calculated automatically by the CFX MANAGER v.2.1 software with default parameters. RNA abundance was calculated as 2−(Ct). Levels of the target genes were normalized against the housekeeping gene, Hprt1, and compared using the ∆∆Ct method ([@bib32]).

Bone marrow transplantation {#s4-11}
---------------------------

C57BL/6J mice received bone marrow from CB~2~-GFP BAC or C57BL/6J male mice. G-irradiation of C57BL/6J recipient male mice (9.5 Gy) was performed in a 137Cs-g IBL 437 C H irradiator (Schering CIS Bio international) at 2.56 Gy/min rate in order to suppress their immune response. Afterwards, approximately 5 × 10^5^ bone marrow cells collected from donors (CB~2~-GFP BAC or C57BL/6J) and transplanted through the retro-orbital venous sinus of the recipient mice. Irradiated mice were inspected daily and were given 150 ml of water with enrofloxacin at 570 mg/l and pH 7.4 (Bayer, Germany) for 30 days to reduce the probability of infection from opportunistic pathogens. Peripheral blood samples (150 μl) were collected by tail bleeding into a tube with 0.5 M EDTA solution to evaluate immune system recovery through flow cytometry 4, 8 and 12 weeks after the bone marrow transplantation.

Flow cytometry {#s4-12}
--------------

For the analyses of hematopoietic cells, a hypotonic lysis was performed to remove erythrocytes. 50 μl of blood was lysed using 500 μl of ACK (Ammonium-Chloride-Potassium) Lysing Buffer (Lonza, Walkersville) 10 min at room temperature. After the erythrocytes lysis, two washes with PBS were performed prior the incubation with the antibodies for 30 min at 4°C. Cells were stained with the following fluorochrome-coupled antibodies: Allophycocyanin (APC)-conjugated anti-mouse CD11b (1:300; cn.17--0112 eBioscience, USA) to label myeloid cells, phycoerythrin (PE)-conjugated anti-mouse B220 (1:100; cn.12--0452, eBioscience, USA) for B lymphocytes and phycoerythrin/cyanine (PE/Cy7)-conjugated anti-mouse CD3, 1:100; cn.100320, BioLegend, USA) for T lymphocytes. Immunofluorescence of labeled cells was measured using a BD LSR II flow cytometer. Dead cells and debris were excluded by measurements of forward- versus side-scattered light and DAPI (4′,6-diamino-2-phenylindole) (Sigma) staining. Gates for the respective antibodies used were established with isotype controls and positive cell subset controls. Data analysis was carried out using FACSDiva version 6.2 software (BD biosciences).

Immunohistochemistry {#s4-13}
--------------------

Mice were sacrificed 2 weeks after the PSNL/sham surgery and L3-L5 dorsal root ganglia were collected to quantify GFP+ cells in mice transplanted with bone marrow cells of CB~2~-GFP or C57BL6/J mice. Ganglia were freshly extracted and fixed in 4% paraformaldehyde during 25 min at 4°C. After 3 × 5 min washes with phosphate buffered saline (PBS) 0.1 M (pH 7.4), were preserved overnight in a 30% sucrose solution in PBS 0.1 M containing sodium azide 0.02%. 24 hr later, ganglia were embedded in molds filled with optimal cutting temperature compound (Sakura Finetek Europe B.V., Netherlands) and frozen at −80°C. Samples were sectioned with a cryostat at 10 µm, thaw-mounted on gelatinized slides and stored at −20°C until use. Dorsal root ganglia sections were treated 1 hr with 0.3 M glycine, 1 hr with oxygenated water 3% (Tyramide Superboost Kit, [B40922](https://www.thermofisher.com/order/catalog/product/B40922), Thermo Fisher, USA) and, after 3 × 5 min washes with PBS 0.01 M, 1 hr with blocking buffer. Samples were incubated 16 hr at room temperature with rabbit anti-GFP (1:2000, A11122, Thermo Fisher, USA) antibody. After 3 × 10 min washes with PBS 0.01 M, sections were incubated with anti-rabbit poly-HRP-conjugated secondary antibody for 1 hr and washed 4 × 10 min. Alexa Fluor tyramide reagent was applied for 10 min and then the Stop Reagent solution for 5 min (Tyramide Superboost Kit). Afterwards samples were incubated 2 hr at room temperature with primary antibodies diluted in blocking buffer (PBS 0.01 M, Triton X-100 0.3%, Normal Goat Serum 10%). The following primary antibodies were used: rabbit anti-peripherin (1:200, PA3-16723, Thermo Fisher, USA), rabbit anti-β-III tubulin (1:1000, ab18207, Abcam, UK), rat anti-CD45R/B220 APC (1:500, Clone RA3-6B2, 103229, Biolegend, USA) and rat anti-F4/80 (1:500, Clone A3-1, MCA497GA, Biorad, USA). After 3 × 5 min washes, all sections were treated with goat secondary antibodies from Abcam (UK) for 1 hr at room temperature: anti-rabbit Alexa Fluor 555 (1:1000, ab150078) and anti-rat Alexa Fluor 555 (1:1000, ab150158). Samples were then washed with PBS 0.01 M and mounted with 24 × 24 mm coverslips (Brand, Germany) using Fluoromount-G with DAPI (SouthernBiotech, USA).

Microscope image acquisition and processing {#s4-14}
-------------------------------------------

Confocal images were taken with a Leica TCS SP5 confocal microscope (Leica Microsystems, Mannheim, Germany) on a DM6000 stand using 20 × 0.7 NA Air and 63 × 1.4 NA Oil Immersion Plan Apochromatic lenses. Leica Application Suite Advanced Fluorescence software (Leica Microsystems, Mannheim, Germany) was used to acquire the images and DAPI, Alexa 488 and Alexa 555 channels were taken sequentially. Images of DAPI were taken with 405 nm excitation and emission detection between 415 and 480 nm; images of Alexa 488 were taken with 488 nm excitation and emission detection between 495 and 540 nm; and images of Alexa 555 were taken with 543 nm excitation and emission detection between 555 and 710 nm. Room temperature was kept at 22 ± 1°C during all imaging sessions. All images were equally processed and quantified with Fiji software (National Institutes of Health, USA). To determine the percentage of dorsal root ganglia area occupied by GFP (+) neurons auto-threshold ('Otsu') was set between 0--50 in all images and then converted to mask. Afterwards, operations included Close, Fill holes and Watershed neurons for separation and particles between 100--100000 pixel units and circularity 0.2--1.0 were counted. To analyze the number of GFP+ cells per dorsal root ganglia area, background was subtracted from all images (rolling = 5), set to an auto-threshold ('Default') between 0--70 and converted to mask. Particles considered GFP+ cells were nucleated, 7--100 microns^2^ and 0.9--1.0 circularity.

Statistical analysis {#s4-15}
--------------------

Self-administration and nociceptive behavioral data were analyzed using a linear mixed model with three (surgery, day and dose) or two factors (day and genotype or antibody treatment) and their interactions. For the covariance structure of the repeated measures, a diagonal matrix was chosen. Bonferroni post hoc analysis was performed when pertinent. Areas Under the Curve (AUCs) of time-courses for operant responding were analyzed using two-way analysis of variance (ANOVA). Active and inactive responses were analyzed taking into account surgery and dose effects in the dose-response experiments, and active/inactive and genotype or antibody treatment in the knockout and antibody experiments. Anxiety-like behavior was analyzed using two-way ANOVA (surgery and dose for dose-response experiments), one-way ANOVA (genotype of conditional knockouts) or t-tests (constitutive knockout and antibody treatment), followed by Bonferroni adjustments when required. Mechanical and thermal thresholds in Nav1.8 and TRPA1 knockout mice treated with JWH133 were analyzed using three-way repeated measures ANOVA with surgery and genotype as between-subject factors and treatment as within-subject factor, followed by Bonferroni post-hoc test when appropriate. Immunohistochemistry of bone marrow-transplanted mice was analyzed using the Bonferroni-Dunn's test to adjust for multiple comparisons after multiple t-tests, and qPCR results after antibody treatments were compared with t-tests. IBM SPSS 19 (SPSS Inc, Chicago, IL) and STATISTICA 6.0 (StatSoft, USA) software were used to analyze the data, and differences were considered statistically significant when p value was below 0.05. All experimental data and statistical analyses of this study are included in the manuscript and its supplementary files. Raw data and results of statistical analyses are provided in the respective Source Data Files and their containing data sheets.
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In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

**Acceptance summary:**

To what extent cannabinoids are effective against chronic pain is still unclear. Using self-administration of a selective CB~2~ receptor antagonist in mice, the authors report that expression of the CB~2~ receptor in both neurons and lymphocytes underlies a complex interaction that can regulate spontaneous pain following nerve injury.

**Decision letter after peer review:**

Thank you for submitting your article \"Protective role of neuronal and lymphoid cannabinoid CB~2~ receptors in neuropathic pain\" for consideration by *eLife*. Your article has been reviewed by two peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Christian Büchel as the Senior Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

As the editors have judged that your manuscript is of interest, but as described below that additional experiments are required before it is published, we would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). First, because many researchers have temporarily lost access to the labs, we will give authors as much time as they need to submit revised manuscripts. We are also offering, if you choose, to post the manuscript to bioRxiv (if it is not already there) along with this decision letter and a formal designation that the manuscript is \"in revision at *eLife*\". Please let us know if you would like to pursue this option. (If your work is more suitable for medRxiv, you will need to post the preprint yourself, as the mechanisms for us to do so are still in development.)

Both reviewers found many positive aspects to your manuscript. However, although reviewer \#1 believes that the concerns could be addressed without providing additional experimental data, reviewer 2 has identified some significant concerns that do need additional information. The specific experiments that are indicated address the underlying mechanism, including the extent to which receptor expression on sensory neurons is involved and most importantly, the contribution of TRPA1. We appreciate that the present COVID-19 pandemic will make it impossible to complete the requested studies within the normal 2 month period, which will involve new mouse crosses, we are willing to accept a revised manuscript when you are able to return to the laboratory and complete the studies.

Reviewer \#1:

This is a very interesting paper. While demonstration of CB~2~ receptor agonist self-administration in rodent models of chronic pain is not in itself novel, there is a sufficient body of additional novel and exciting work in this paper to set it apart from previously published work. In particular, the mechanistic dissection using tissue-specific KO mice, coupled with the demonstration of that CB~2~ receptor-expressing lymphocytes infiltrate peripheral neurons, and to a greater degree in nerve-injured versus sham mice. The anxiety-related results are also very interesting. The paper is well-written and the results, for the most part, are clear.

1\) While there are significant novel results and important conclusions that can be and have been drawn from the work, the mechanism underlying the increased self-administration of JWH133 in PSNL mice has still not been fully elucidated. The authors have shown it is CB~2~ receptor-dependent, but not due to CB~2~ receptors in neurons or monocyte-derived cells. Neither does it appear to be due to CB~2~ receptors on infiltrating lymphocytes. So the question still remains as to what mechanism or target is mediating the effect. I think the Discussion should address this limitation in more detail, and put forward some potential mechanisms.

2\) Is it possible that there could be some involvement for CB~1~ receptors? JWH133 is relatively selective for CB~2~ over CB~1~, but to my knowledge it does still have some affinity for (and potential activity at) CB~1~. How can the authors rule out a potential involvement of CB~1~ in the self-administration of JWH133 after PSNL.

3\) Given the anxiety-related aspect (and indeed the self-administration/pain aspect), why did the authors not look at whether lymphocytes expressing CB~2~ also infiltrate brain neurons? It would be very interesting to know if they infiltrate neurons in brain regions such as the amygdala, PFC, PAG and other regions known to be important in pain, anxiety and drug self-administration in pain models.

Reviewer \#2:

This is an interesting paper that addresses and important and timely subject, namely identification of novel non opioid approaches to pain management. The authors direct their attention the CB~2~ receptor. Using perhaps the best characterized, and quite selective CB~2~ ligand, the authors implicated CB~2~ receptors in both neuronal and non-neuronal cells in the spontaneous pain that occurs in a partial nerve injury model in the mouse. The studies largely used either mice in which the CB~2~ receptor was deleted in all cells only in neurons, or selectively in monocyte derived cells.

There are many intriguing findings in the paper, however, one is left with the feeling that there are hints at mechanisms, but nothing definitive is established. And major questions, which I believe could have been addressed with more selective Cre-mediated deletion of the receptor, are never answered. Hints here and there, but nothing definitive.

The authors focus on sensory neurons and the non-neuronal cells that surround the neuronal cell bodies in the DRG. How might the neurons in the DRG, which they appear to presume must be mediating the input that drives spontaneous pain, not be relevant to acute pain processing? The previous report of Soethoudt et al., 2017, which defined the specificity of JWH133, found that this compound is without effect on acute pain even at doses up to 100mg/kg. I am not sure how to translate that dose to the iv administration in the present paper, but my assumption is that the 100mg/kg dose is at least equivalent. Granted JWH133 is not potent, but then how does it affect spontaneous pain?

The most straightforward test of the DRG neurons is to delete the CB~2~ receptor from neurons, using one of several selective Cre lines (e.g. NaV1.8-Cre). This is particularly important as the authors highlight the apparent translocation of the CB~2~ receptor from non-neuronal cells around the DRG to neurons. But they only used peripherin to mark the neurons, so that any change in myelinated afferents would be missed. As neurons are the only structure that can get information into the spinal cord, do the authors propose that it is this small 4% of DRG neurons that is key?

Perhaps the most glaring piece missing as to mechanism is the fact, acknowledged by the authors, that JWH133 has a significant action at TRPA1, which is expressed by sensory neurons. Most importantly, the authors found that the CB2R null only had 50% reduced nose poke for JWH133. Clearly, JWH133 must exert its effect, at least in part, on another target. In their Abstract, the authors are very careful concerning this finding, writing that \"\"While constitutive deletion of CB2r disrupted JWH133-taking behavior....\". In other words JWH133 disrupted, it did not prevent or eliminate the behavior. So clearly, there is something else mediating JWH133\'s effects. Studying JWH133 effects in the TRPA1 mutant, and ideally in the mouse in which TRPA1 is selectively deleted from sensory neurons, is critical to understanding this drug\'s actions. Results from that study would add greatly to the authors study.

Also, as TRPA1 is expressed in sensory neurons, are they now proposing that TRPA1 only contributes to spontaneous pain? That is certainly not the case. In fact, a previous study did report that JWH133 blocked pain behaviors provoked by AITC, a TRPA1 agonist. A simple experiment would be to test the effect of JWH133 against 0.5% formalin evoked nocifensive behaviors. As for AITC, 0.5% formalin evoked behaviors are lost in the TRPA1 ko.

Another simple experiments that would get at mechanism is to examine the effect of JWH133 on nerve injury provoked microglial activation in the dorsal horn. If a decreased activation were demonstrated, the case would be much stronger that the drug is acting on sensory neurons.

Concerns about the immunohistochemistry: First, the images presented are not all that convincing, and particularly difficult to read given that the percentage of double labeled neurons is small. It is also very odd that the authors had to use TSA amplification. Also there is no mention of controls for antibody specificity.
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Author response

> Reviewer \#1:
>
> \[...\] 1) While there are significant novel results and important conclusions that can be and have been drawn from the work, the mechanism underlying the increased self-administration of JWH133 in PSNL mice has still not been fully elucidated. The authors have shown it is CB~2~ receptor-dependent, but not due to CB~2~ receptors in neurons or monocyte-derived cells. Neither does it appear to be due to CB~2~ receptors on infiltrating lymphocytes. So the question still remains as to what mechanism or target is mediating the effect. I think the Discussion should address this limitation in more detail, and put forward some potential mechanisms.

We agree with the reviewer that this is a limitation of the work and the following paragraph was added to the Discussion section, as requested:

"While we identify CB~2~-expressing neurons and lymphocytes as cellular entities involved in spontaneous and evoked neuropathic pain, the efficacy of the CB~2~ agonist eliciting its own self-administration to alleviate pain was only disrupted in constitutive CB~2~ knockout mice. \[...\] Vascular cells may represent alternative participants of this behavior since JWH133 showed local vasodilatory effects (McDougall and Thomson, 2008) and endothelial functional CB~2~ receptor was found in cerebral microvasculature (Ramirez et al., 2012; Onaivi et al., 2012)."

We also explained further the self-administration results on the neuronal knockouts to highlight neuronal involvement on affective-motivational responses:

"Thus, increased self-administration suggests an enhanced affective-motivational component of pain and not reduced drug efficacy on this aspect, since nerve-injured C57BL6/J mice exposed to the low JWH133 dose did not show compensatory increased self--administration (Figure 1)."

> 2\) Is it possible that there could be some involvement for CB~1~ receptors? JWH133 is relatively selective for CB~2~ over CB~1~, but to my knowledge it does still have some affinity for (and potential activity at) CB~1~. How can the authors rule out a potential involvement of CB~1~ in the self-administration of JWH133 after PSNL.

Partial involvement of CB~1~ receptor activity in JWH133 self-administration after PSNL cannot be completely ruled out from our data. We included this paragraph in the Discussion section to take into account this possibility:

"Another possibility is a minor involvement of CB~1~ receptor in JWH133 self-administration after the nerve injury, since this compound is a selective CB~2~ agonist that exhibited 40-fold higher affinity for mouse CB~2~ than for CB~1~ receptor (Soethoudt et al., 2017). \[...\] Since JWH133 selectivity for human CB~2~ vs. human CB~1~ is higher (153-fold selectivity), we do not foresee any concern with CB~1~-related behavioral effects using similar molecules in humans."

> 3\) Given the anxiety-related aspect (and indeed the self-administration/pain aspect), why did the authors not look at whether lymphocytes expressing CB~2~ also infiltrate brain neurons? It would be very interesting to know if they infiltrate neurons in brain regions such as the amygdala, PFC, PAG and other regions known to be important in pain, anxiety and drug self-administration in pain models.

We agree on the interest of determining lymphocyte infiltration in pain, anxiety and reinforcement-related brain regions and the following sentence was included in the Discussion section:

"Our data also underscore the interest of investigating the role of lymphoid cells in brain regions involved in pain, anxiety or negative reinforcement during chronic neuroinflammatory processes."

Given the previous results demonstrating hippocampal neuronal CB~2~ receptor activity (Stempel et al., 2016), we looked for mRNA changes of neuronal and immune markers in the hippocampus of the CB~2~ knockout mice and their control littermates. However, the negative results obtained in our experimental conditions (see [Author response image 1](#sa2fig1){ref-type="fig"}) discouraged us of continuing biochemical determinations in this region.

![](elife-55582-resp-fig1){#sa2fig1}

> Reviewer \#2:
>
> \[...\] There are many intriguing findings in the paper, however, one is left with the feeling that there are hints at mechanisms, but nothing definitive is established. And major questions, which I believe could have been addressed with more selective Cre-mediated deletion of the receptor, are never answered. Hints here and there, but nothing definitive.
>
> The authors focus on sensory neurons and the non-neuronal cells that surround the neuronal cell bodies in the DRG. How might the neurons in the DRG, which they appear to presume must be mediating the input that drives spontaneous pain, not be relevant to acute pain processing? The previous report of Soethoudt et al., 2017, which defined the specificity of JWH133, found that this compound is without effect on acute pain even at doses up to 100mg/kg. I am not sure how to translate that dose to the iv administration in the present paper, but my assumption is that the 100mg/kg dose is at least equivalent. Granted JWH133 is not potent, but then how does it affect spontaneous pain?

DRG neurons could certainly mediate spontaneous pain after peripheral nerve injury in our experimental conditions. However, peripheral CB~2~ do not play an important role in acute pain processing (Hanus et al., 1999; Naguib et al., 2008). Indeed, CB~2~ agonists have poor efficacy in the absence of ongoing inflammatory conditions (Bie et al., 2018), which emphasizes the relevance of the presence of pathological conditions for the effects of JWH133. Since the mouse cannabinoid triad in the Soethoudt paper was in principle conducted in naïve mice exposed to JWH133, a general lack of efficacy could be expected even considering the high doses used. In our experiments in nerve-injured mice, 5 and 10 mg/kg i.p. produced significant mechanical antinociception above 50% MPE, and we previously observed significant effects with 1 and 5 mg/kg i.p. during chronic knee inflammation (La Porta et al., Pain, 2015). Both inflammatory and neuropathic pain conditions are different to those used by Soethoudt et al., 2017, to evaluate acute pain in naïve mice. According to the Soethoudt paper, i.v. doses of 1.6 mg/kg have a half-life of 1.1 hour. The i.v. dose used in our work is lower (0.3 mg/kg) and should induce short half-life sub-maximal responses sufficient to promote contingent and repeated operant self-administration in order to relieve non-evoked pain under these neuropathic pain conditions.

> The most straightforward test of the DRG neurons is to delete the CB~2~ receptor from neurons, using one of several selective Cre lines (e.g. NaV1.8-Cre). This is particularly important as the authors highlight the apparent translocation of the CB~2~ receptor from non-neuronal cells around the DRG to neurons.

We conducted an additional experiment to evaluate JWH133 antinociceptive effects in CB~2~ Nav1.8-Cre+ mice lacking CB~2~ receptor in Nav1.8 peripheral neurons. Conditional knockout mice and their wild-type littermates were subjected to the partial sciatic nerve ligation or the sham procedure and tested for mechanical and thermal hypersensitivity after administration of vehicle or JWH133 at doses of 5 and 10 mg/kg. We observed similar effects of JWH133 inhibiting mechanical and thermal hypersensitivity of Nav1.8-Cre+ and Cre Negative mice. Together with the results obtained in the Syn-Cre+ mice and the bone-marrow transplantation experiments, these results suggest the involvement of CB~2~ receptor from central locations and/or of CB~2~ receptor translocated from non-neuronal cells. The results are included in Figure 3---figure supplement 2.

The line of mice used to genetically disrupt CB~2~ receptors in Nav1.8 cells was less sensitive than other mouse lines to promote thermal hyperalgesia after sciatic nerve injury and was therefore less sensitive to the anti-hyperalgesic effect of JWH133 in the plantar test under our experimental conditions, although a significant general effect of JWH133 was revealed at the dose of 10 mg/kg in both genotypes. Average baseline thresholds or contralateral paw thresholds did not show significant differences between both strains of mice subjected to the neuropathic pain model (see [Author response image 2](#sa2fig2){ref-type="fig"}).
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A new figure supplement was added to Figure 3 (Figure 3---figure supplement 2). Details of the methods were included (Materials and methods subsections "Animals", "Drugs" "Statistical analysis"), results were added to the Results section (subsection "Participation of neuronal and monocyte CB~2~ receptor in neuropathic pain symptomatology") and source data files (Figure 3---figure supplement 2---source data 1), and discussed in the Discussion section (third paragraph).

> But they only used peripherin to mark the neurons, so that any change in myelinated afferents would be missed. As neurons are the only structure that can get information into the spinal cord, do the authors propose that it is this small 4% of DRG neurons that is key?

As indicated in the Materials and methods section (subsection "Immunohistochemistry"), we used a mixture of anti-peripherin and anti-β-III tubulin antibodies: "rabbit anti-peripherin (1:200, PA3-16723, Thermo Fisher, USA), rabbit anti-β-III tubulin (1:1000, ab18207, Abcam, UK)". In the previous version of the manuscript, we included by mistake in the Materials and methods the anti-neurofilament heavy antibody and this mistake has been now corrected. The rationale of using both anti-peripherin and anti-β-III tubulin was to mark all myelinated and non-myelinated neurons, since this anti β-III tubulin is known to miss some percentage of unmyelinated neurons and peripherin only labels unmyelinated ones. We apologize for this mistake in the Materials and methods section of the previous version of the manuscript.

> Perhaps the most glaring piece missing as to mechanism is the fact, acknowledged by the authors, that JWH133 has a significant action at TRPA1, which is expressed by sensory neurons. Most importantly, the authors found that the CB2R null only had 50% reduced nose poke for JWH133. Clearly, JWH133 must exert its effect, at least in part, on another target. In their Abstract, the authors are very careful concerning this finding, writing that \"While constitutive deletion of CB2r disrupted JWH133-taking behavior....\". In other words JWH133 disrupted, it did not prevent or eliminate the behavior. So clearly, there is something else mediating JWH133\'s effects. Studying JWH133 effects in the TRPA1 mutant, and ideally in the mouse in which TRPA1 is selectively deleted from sensory neurons, is critical to understanding this drug\'s actions. Results from that study would add greatly to the authors study.

An additional experiment was performed to compare JWH133 efficacy in wild-type (WT) and TRPA1 constitutive knockout mice (TRPA1 KO) under a C57BL/6J background. Mice were subjected to the partial sciatic nerve ligation or to the sham procedure and after 7 days were tested for mechanical and thermal hypersensitivity to evaluate the effect of vehicle and JWH133 at the doses of 5 and 10 mg/kg. We observed similar effects of JWH133 inhibiting mechanical hypersensitivity in TRPA1 KO and WT mice. Interestingly, TRPA1 KO mice showed a prominent inhibition of neuropathic thermal hypersensitivity. In spite of this lack of sensitivity, a significant general JWH133 effect was observed in nerve-injured mice also in thermal sensitivity, regardless of the genotype of the mice.

The results on mechanical sensitivity show that the effects of the CB~2~ receptor agonist are retained in the TRPA1 KO mice, suggesting that these effects are not due to an interaction of the drug with the TRPA1 receptor. The lack of thermal hypersensitivity observed in the TRPA1 KO mice may occlude possible JWH133 effects on neuropathic thermal hyperalgesia through TRPA1. However, a significant effect of JWH133 was observed in both strains of mice after the nerve injury (10 mg/kg dose), showing that at least the CB~2~ receptor is involved in the inhibitory effect on thermal hyperalgesia. Baseline or contralateral paw thresholds did not show significant differences between TRPA1 KO and WT mice subjected to the neuropathic pain model ([Author response image 3](#sa2fig3){ref-type="fig"}).
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A new figure supplement was added to Figure 2 (Figure 2---figure supplement 2). Details of the methods were incorporated (Materials and methods subsections "Animals", "Drugs" and "Statistical analysis") and results were added to the Results section (subsection "CB~2~ receptor mediates JWH133 effects on spontaneous pain alleviation") and source data file (Figure 2---figure supplement 2---source data 1), and discussed in the Discussion section (second paragraph).

> Also, as TRPA1 is expressed in sensory neurons, are they now proposing that TRPA1 only contributes to spontaneous pain? That is certainly not the case. In fact, a previous study did report that JWH133 blocked pain behaviors provoked by AITC, a TRPA1 agonist. A simple experiment would be to test the effect of JWH133 against 0.5% formalin evoked nocifensive behaviors. As for AITC, 0.5% formalin evoked behaviors are lost in the TRPA1 ko.

These studies and our additional new results using TRPA1 knockout mice were added to the Discussion section:

"Our results with the nerve-injured TRPA1 knockout mice revealed that JWH133 preserves its efficacy inducing antinociception in the absence of this receptor. \[...\] Interestingly, TRPA1 deletion prevented the development of thermal hyperalgesia after the nerve injury in our study and formalin (0.5%) evoked nocifensive behaviors are also lost in the TRPA1 knockout (McNamara et al., 2007)."

> Another simple experiments that would get at mechanism is to examine the effect of JWH133 on nerve injury provoked microglial activation in the dorsal horn. If a decreased activation were demonstrated, the case would be much stronger that the drug is acting on sensory neurons.

Previous studies have reported a relevant role of CB~2~ receptor activity in the control of nociceptive responses through central areas such as the rostral ventromedial medulla (Li et al., 2017; Song et al., 2018). Therefore, an effect of JWH133 on spinal microglial activation could be the result of modified descending input from this pain-modulating region. These previous results also underline a broad role of microglia in pain control that seems to be not only limited to the spinal dorsal horn.

> Concerns about the immunohistochemistry: First, the images presented are not all that convincing, and particularly difficult to read given that the percentage of double labeled neurons is small. It is also very odd that the authors had to use TSA amplification. Also there is no mention of controls for antibody specificity.

Additional images showing higher levels of double-labeled neurons have been added. They constitute now Figure 4---figure supplement 5 (A, CB~2~-GFP Sham; B, CB~2~-GFP PSNL) and Figure 4---figure supplement 6 (Amplified Merged Images of CB~2~-GFP Sham and CB~2~-GFP PSNL from Figure 4---figure supplement 5).

We used Tyramide Signal Amplification (TSA) due to low signal-to-background ratio, which could be associated to the sample processing or to low expression levels. Specificity tests for TSA are shown in Figure 4---figure supplement 7. Controls for antibody specificity are included as Figure 4---figure supplement 8. All supplements are mentioned in the legend of Figure 4.
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